NEW YORK, NY / ACCESS Newswire / November 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sanara MedTech Inc. ("Sanara MedTech Inc.") (NASDAQ:SMTI) concerning possible violations of federal securities laws.
On November 11, 2025, Sanara announced that it would be "discontinuing operations of [its Tissue Health Plus ("THP") program] to improve its operating efficiency and reallocate resources to its core surgical business." The following day, before market hours, Sanara released its third quarter 2025 financial results, reporting that its "net loss from discontinued operations . . . was $31.2 million," which "includes a noncash asset impairment charge of $26.5 million . . . related to the discontinued operations of THP."
Following this news, Sanara’s stock price fell over 24% on November 12, 2025. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
COMTEX_470427212/2457/2025-11-21T14:32:32